
Advancing Access to Genetic Treatments
Based on CRISPR Technology
At NPREMA, in collaboration with Leading Edge Global, we are committed to advancing access to CRISPR technology-based gene therapy to cure sickle cell anemia. Through education, advocacy, and grassroots fundraising, we aim to empower communities and ensure equitable healthcare solutions by supporting cutting-edge genetic therapies that have the potential to transform lives.
Promoting Access and Awareness
through Education and Advocacy
The NPREMA Initiative:
Expanding Access to CRISPR Gene-Editing Treatments for Sickle Cell Anemia
At NPREMA, we are leading a transformative initiative focused on expanding access to FDA-approved CRISPR treatments for sickle cell anemia. Through a comprehensive approach encompassing education, advocacy, and grassroots fundraising, our goal is to ensure that every individual affected by sickle cell disease can benefit from this groundbreaking therapy. By collaborating with healthcare professionals, policymakers, and research labs, we are committed to raising awareness, fostering innovation, and advocating for equitable healthcare solutions that can change lives.
Make an Impact With Us
Meet the Team
Our team of diverse volunteers is composed of dedicated students from various universities, including Adelphi University, NYU, Rutgers, Yeshiva University, and Baruch College.
The Pulse: News and Updates















